Bli medlem
Bli medlem

Du är här

2016-01-11

CORRECTION: Active Biotech: Information regarding the clinical study LEGATO-HD

This is a correction of the announcement from 08:30 11.01.2016 CET. Reason for the correction: Swedish version only that is corrected
Lund, January 11, 2016
- Active Biotech (Nasdaq Stockholm: ACTI) today announces that its partner
Teva Pharmaceutical Industries Ltd, will amend the trial design in a Phase 2
study of laquinimod in Huntington's disease. The amendment consists of
dropping the highest of three doses (1.5 mg/day) in the trial while keeping
two remaining active doses (0.5 and
1 mg/day) unchanged. This is a precautionary measure in the interest of
patient safety being suggested by Teva to the Data Safety Monitory Board
(DSMB) for the LEGATO-HD trial.

The DSMB accepted the recommendation after reviewing data which observed
cardiovascular incidents in patients receiving the high doses of laquinimod
in two multiple sclerosis trials as reported on January 4, 2016. No
cardiovascular events have been observed for any dose of the LEGATO-HD trial.
Teva will continue in its commitment to study laquinimod in Huntington's
disease.

Currently the mechanism of the cardiovascular events in the MS trials remains
unknown. Although no specific time-to-event patterns have been identified,
cardiovascular risk factors and demographics may play a role.

For further information, please contact:

Tomas Leanderson, President&CEO
Tel +46 46 19 20 95

Hans Kolam, CFO
Tel +46 46 19 20 44

Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active Biotech AB (publ)

(Nasdaq Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally
administered small molecule with unique immunomodulatory properties, is in
pivotal Phase 3 development for the treatment of relapsing remitting multiple
sclerosis. Also, laquinimod is in Phase 2 development for the treatment of
primary progressive multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the ISI, ANYARA and paquinimod
projects. Please visitwww.activebiotech.comfor more information.

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. This information was provided to the media
for publication at 8:30 am CET on January 11, 2016.
Information regarding the clinical study LEGATO-HD
http://hugin.info/1002/R/1977862/724228.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

HUG#1977862

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.